Rapid curation of a robust, recallable donor pool of CMV seropositive donors for delivery of RUO and GMP
Rapid curation of a robust, recallable donor pool of CMV seropositive donors for delivery of RUO and GMP
6 PagesIn 2015, the FDA approved the monoclonal antibodies daratumumab and elotuzumab for treating multiple myeloma (MM), utilizing antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells. Research identified a rare NK cell subset with enhanced ADCC in CMV+ individuals, prompting development of an expansion method for these cells as a therapy. OrganaBio provided a robust supply of leukopaks from CMV+ donors for this purpose, demonstrating efficient project management, donor screening, and international logistics for delivering fresh leukopaks to a Singapore CDMO, significantly improving donor suitability rates and ensuring timely progress in MM therapy development.
